NewTimeSpace News: HENGRUI PHARMA (01276.HK) released an announcement on January 26, 2026, disclosing that it has recently received the "Drug Clinical Trial Approval Notice" for SHR-1049 Injection issued by the National Medical Products Administration (NMPA), and will initiate the clinical trial of the drug in the near future.

According to the announcement, SHR-1049 Injection is an injectable formulation, and the application item this time is for clinical trials. As an innovative anti-tumor drug independently developed by HENGRUI PHARMA, its core indication is the treatment of advanced solid tumors. As of the date of the announcement, the cumulative R&D investment in the SHR-1049 Injection project is approximately RMB 26 million.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.